Liposomal Irinotecan and Apatinib in ES-SCLC
Recruiting · NCT06749691 · Interventional (participants receive a specific treatment) · Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
View the official record on ClinicalTrials.gov →Interventions studied
Liposomal Irinotecan and Apatinib
What this trial is about
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age range of 18-75 years;
- Expected survival period ≥ 12 weeks;
- At least one measurable lesion (according to RECIST V 1.1);
- For patients who have failed first-line or second-line treatment.
Exclusion criteria
- Have received any systemic treatment targeting VEGF or VEGFR in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib.
- Active or uncontrolled severe infection (CTCAE 5.0 ≥ 2) and/or antibiotic treatment within 2 weeks prior to enrollment;
- There are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction;
- Those deemed unsuitable for inclusion by doctors;
Where it is running
1 location listed.
- Second Affiliated Hospital of Zhejiang University - Hangzhou, Zhejiang, China